Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
75.7M
-
Shares change
-
+3.53M
-
Total reported value, excl. options
-
$620M
-
Value change
-
+$32.9M
-
Put/Call ratio
-
0.47
-
Number of buys
-
68
-
Number of sells
-
-73
-
Price
-
$8.19
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2019
196 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2019.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.7M shares
of 236M outstanding shares and own 32.04% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (24.5M shares), VANGUARD GROUP INC (5.8M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5.66M shares), Nantahala Capital Management, LLC (4.94M shares), STATE STREET CORP (3.38M shares), Novo Holdings A/S (3.1M shares), PERCEPTIVE ADVISORS LLC (1.7M shares), RICE HALL JAMES & ASSOCIATES, LLC (1.55M shares), Consonance Capital Management LP (1.43M shares), and MORGAN STANLEY (1.33M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.